What Did We Learn From IMpower010 in Resectable NSCLC

What the New KRAS Inhibitor Means for Lung Cancer

Last month, the FDA granted accelerated approval of sotorasib (Lumakras) for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), following the results of the phase II CodeBreaK 100 trial, data from which were presented during the recent virtual American Society of Clinical Oncology annual meeting. In this second of four exclusive episodes, MedPage Today brought together three leaders in the field —  moderator Vinay Prasad, MD, …

What Did We Learn From IMpower010 in Resectable NSCLC

Genomic Test in Lung Cancer: Waiting Is the Hardest Part

— Our expert roundtable discusses how they the treat NSCLC patients who are waiting on NGS results Next-generation sequencing (NGS) is recommended by the National Comprehensive Cancer Network (NCCN) for all patients with non-small cell lung cancer (NSCLC). Several studies at the recent American Society of Clinical Oncology virtual annual meeting explored the application of biomarker testing in the U.S., as well …

What Did We Learn From IMpower010 in Resectable NSCLC

What Did We Learn From IMpower010 in Resectable NSCLC

At the recent virtual American Society of Clinical Oncology annual meeting, results of the phase III IMpower010 trial demonstrated that adjuvant atezolizumab (Tecentriq) for patients with stage IB to IIIA non-small cell lung cancer (NSCLC) improved disease-free survival in patients with high PD-L1 expression. In this first of four exclusive episodes, MedPage Today brought together three leaders in the field —  moderator Vinay Prasad, MD, of the University …